Adaptive Biotechnologies Corporation (ADPT) vs NeoGenomics, Inc. (NEO)
- Adaptive Biotechnologies Corporation ADPT 24.02 −6.10%
- NeoGenomics, Inc. NEO 16.65 −3.48%
Adaptive Biotechnologies Corporation and NeoGenomics, Inc. are both Diagnostics & Research companies. Adaptive Biotechnologies Corporation is the larger, with a market value of $4.1B against $2.2B — 1.8× the size. Adaptive Biotechnologies Corporation grew revenue faster over the last twelve months: 50.1% against 11.2%. NeoGenomics, Inc. has the higher net margin (−6.77% vs −20.7%) and the higher return on invested capital (−4.20% vs −16.6%). Across the 18 metrics below, NeoGenomics, Inc. leads on 12 and Adaptive Biotechnologies Corporation on 6.
Valuation
Profitability
| Metric | ADPT | NEO | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 75.57% | 43.92% | 50.89% |
| Operating margin | (12.16%) | (8.93%) | (8.57%) |
| Net margin | (20.73%) | (6.77%) | (6.37%) |
| Free cash flow margin | (7.80%) | (0.69%) | 0.00% |
| Return on equity | (38.68%) | (6.33%) | (2.92%) |
| Return on assets | (11.23%) | (3.78%) | (6.71%) |
| Return on invested capital | (16.57%) | (4.20%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack